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Understanding the mechanisms regulating pluripo-
tency inembryonicand inducedpluripotentstemcells
is required to ensure their safe use in clinical applica-
tions. Glycogen synthase kinase-3 (GSK-3) has
emerged as an important regulator of pluripotency,
based primarily on studies with small-molecule
GSK-3 inhibitors. Here, we use mouse embryonic
stem cells (ESCs) lacking GSK-3 to demonstrate that
a single GSK-3 substrate, b-catenin, controls the
ability of ESCs to exit the pluripotent state and to
differentiate into neurectoderm. Unexpectedly, the
effects of b-catenin on pluripotency do not appear
to be dependent on TCF-mediated signaling, based
on experiments utilizing a b-catenin C-terminal trun-
cation mutant or highly efficient dominant-negative
TCF strategies. Alternatively, we find that stabilized
b-catenin forms a complex with and enhances the
activity of Oct-4, a core component of the transcrip-
tional network regulating pluripotency. Collectively,
our data suggest previously underappreciated, diver-
gent TCF-dependent and TCF-independent roles for
b-catenin in ESCs.
INTRODUCTION
The advent of induced pluripotent stem cell technology has re-
sulted in renewed optimism with respect to using pluripotent or
multipotent stem cells for applications in regenerative medicine.
Our understanding of the signalingmechanisms that regulate the
acquisition and retention of the pluripotent state remains limited
and must be improved if pluripotent stem cells are to be used
safely for clinical purposes. Recently, glycogen synthase
kinase-3 (GSK-3) has emerged as an important regulator of plu-
ripotency, based largely on studies with small-molecule GSK-3
inhibitors (Bone et al., 2009; Buehr et al., 2008; Li et al., 2009;
Sato et al., 2004; Ying et al., 2008).
GSK-3 regulates numerous cellular substrates, which include
transcription factors, signaling molecules, and structural pro-214 Cell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc.teins (Doble and Woodgett, 2003). Because of its involvement
in numerous signaling pathways and metabolic processes, the
mechanisms underlying the effects of GSK-3 inhibition on stem
cell pluripotency are unclear. Several mechanisms have been
proposed, including GSK-3’s regulation of c-Myc, Wnt/b-cate-
nin, and PI-3K signaling (Bechard and Dalton, 2009; Bone
et al., 2009; Sato et al., 2004; Storm et al., 2007).
A key GSK-3 substrate is b-catenin, the effector molecule of
the Wnt/b-catenin signaling pathway, which acts as a transacti-
vator of target genes through its interactions with TCF/LEF tran-
scription factors (reviewed in Arce et al., 2006; MacDonald et al.,
2009). GSK-3-mediated phosphorylation of b-catenin results in
its ubiquitination and proteasomal degradation. We have shown
previously that mouse embryonic stem cells (mESCs) devoid
of GSK-3 display extremely high levels of signaling-competent
b-catenin and have a profound block in their capacity to differen-
tiate into cell types of the three germ lineages (Doble et al., 2007).
Most notably, teratomas and embryoid bodies derived from
GSK-3a/b double-knockout (DKO) mESCs exhibited a complete
lack of detectable neurectodermal differentiation.
A correlation between high levels of b-catenin signaling and
blocked neuronal differentiation of mESCs has been observed
in other models where dominant-active b-catenin was overex-
pressed (Haegele et al., 2003) or the b-catenin destruction
complex was disrupted because of mutations in the tumor-
suppressor adenomatous polyposis coli (APC) (Kielman et al.,
2002). Conversely, antagonism of Wnt signaling has been
implicated as a requirement for neural differentiation of mESCs
(Aubert et al., 2002; Caja´nek et al., 2009).
Activation of Wnt/b-catenin signaling has been linked to the
maintenance of the pluripotent state in human and mouse
ESCs (Sato et al., 2004), although these results are somewhat
controversial because self-renewal of the ESCs in Wnt-3a-sup-
plemented medium was not examined over multiple passages
(Bakre et al., 2007; Dravid et al., 2005). Wnt/b-catenin signaling
has also been shown to enhance the induction of pluripotency
in somatic cells, obtained through viral transduction or cell fusion
(Lluis et al., 2008; Marson et al., 2008).
We hypothesized that hyperactivated b-catenin/TCF-
mediated transcriptional activation was responsible for the
phenotype of the DKO mESCs. To address this possibility, we
examined the consequences of blocking b-catenin activity at
the level of TCF-mediated transcription in GSK-3a/b DKO cells
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TCF-Independent b-Catenin Signaling in mESCsthrough the stable expression of dominant-negative TCF1 or
TCF4 (encoded in humans by the genes TCF7 and TCF7L2,
respectively). Surprisingly, although expression of these domi-
nant-negative TCFs efficiently attenuated b-catenin/TCF gene
transactivation, these cells were not rescuedwith respect to their
ability to differentiate into neurectoderm and were capable of
self-renewal in the absence of exogenous factors. However,
we demonstrate that suppression of b-catenin expression,
through shRNA-mediated knockdown, permits the multilineage
differentiation of DKO mESCs. We provide evidence for alterna-
tive b-catenin-mediated signaling, not requiring its TCF-transac-
tivation domain, which reinforces pluripotency and blocks effi-
cient differentiation of mESCs. We show that b-catenin can
form a complex with and modulate the activity of Oct-4 and
propose that this is part of the mechanism through which b-cat-
enin exerts its TCF-independent effects on mESCs. Taken
together, our data suggest that b-catenin is the primary GSK-3
substrate regulating the differentiation of mESCs, through diver-
gent nuclear signaling mechanisms.
RESULTS
Generation of DKO Flp-in Cell Lines
We generated a GSK-3a/b DKO mESC cell line (DKO2.1)
amenable to the generation of isogenic stable cell lines. Starting
with GSK-3a/ mESCs (Doble et al., 2007), we targeted both
GSK-3b loci to generate DKO cells with a single FRT site for
Flp-mediated site-specific recombination (Figure 1A). Trans-
geneswere cloned into pEF5/FRT/V5-D-TOPO (‘‘Flp-In system’’;
Invitrogen) and single-copy transgenic lines were generated in
the DKO2.1 cell line (Figure 1B). We used Southern blotting to
confirm proper targeting (Figure S1A available online).
The DKO2.1 cell line, hereafter referred to as ‘‘DKO,’’ was used
to generate isogenic FLP-in cell lines expressing (1) wild-type
(WT) GSK-3b (DKO-GSK3b), (2) dominant-negative TCF4
(DKO-TCF4DN), (3) dominant-negative TCF1 (DKO-TCF1DN),
and (4) kinase-inactive GSK-3b (DKO-GSK-3b-K85A). PCR anal-
yses with genomic DNA template isolated from each transgenic
cell line andprimers designed to amplify the junction of a properly
recombined Flp-in event yielded bands of the expected size
(Figure S1B).
The DKO mESCs lacked detectable GSK-3a and GSK-3b
protein and displayed high levels of cytosolic b-catenin (Fig-
ure 1C), in keeping with our previous findings (Doble et al.,
2007). Stable expression of wild-type, but not kinase-dead,
GSK-3b normalized cytosolic b-catenin levels. The TCF4DN
protein was readily detected through western blotting with a
Myc tag antibody (Figure 1C) or a TCF4-specific antibody (Fig-
ure S1D). TCF1DN was also easily detected with a TCF1 anti-
body (Figure S1E). The protein levels of TCF4DN and TCF1DN
were markedly higher than their endogenous counterparts
(Figures S1D and S1E). TCF1, TCF3, TCF4, and LEF1 were all
detectable through western blotting with lysates from mESCs
maintained in standardmedium (Figure S1D). LEF1 protein levels
were dramatically decreased and TCF1 levels were slightly lower
in DKO-TCF4DN mESCs, compared to their levels in DKO
mESCs (Figure S1D). By contrast, the amount of TCF3 protein
was not altered by the expression of TCF4DN in DKO mESCs
(Figure S1D). The pluripotent markers Oct4, Nanog, and Sox2Cwere expressed at similar levels in WT and DKOmESCs (Figures
S1F and S1G). DKO-TCF4DNmESCs displayedmodestly higher
levels of Nanog protein (Figure S1F) and transcript (Figure S1G)
compared to WT and DKO mESCs.
The steady-state level of GSK-3b expressed in the DKO-GSK-
3b (WT) and DKO-GSK-3b-K85A cell lines was quantitated
through densitometry (Figure S1C). The amount of GSK-3b in
DKO-GSK-3b cells was approximately 50% of the total amount
of GSK-3 detected in WT mESCs. The steady-state levels of
GSK-3b in DKO-GSK-3b-K85A mESCs was approximately four
times less than that observed in DKO-GSK-3b mESCs. This
probably reflects a requirement for GSK-3 autophosphorylation
in directing the proper folding of GSK-3, which confers enhanced
stability (Lochhead et al., 2006).
The morphology of DKO mESCs (Figure 1D) was identical to
that of our previously generated DKO cell line. DKO-GSK-3b
mESCs had a colony morphology resembling WT mESCs,
whereas cells expressing GSK-3b-K85A or TCF4DN formed
colonies reminiscent of DKO mESCs (Figure 1D). There were
no obvious differences in the cloning efficiencies of FLP-in cell
lines expressing GSK-3b variants, TCF1DN, or TCF4DN. We
present representative data from individual clones for most of
our FLP-in cell lines. Multiple clones were generated for each
type of cell line. As expected for FLP-in cell lines, transgene
expression levels and clone properties were found to be equiva-
lent in independent clones expressing the same transgene.
Dominant-Negative TCF4 and TCF1 Effectively Repress
TCF Activity in DKO mESCs
The high level of TCF activity detected in the DKO cell line was
reduced by 50-fold through stable expression of GSK-3b (Fig-
ure 1E). There was not a marked difference between the levels of
TCF reporter activity assayed in true WT (E14K) or DKO-GSK-3b
mESCs, whereas DKO-GSK-3b-K85AmESCs displayed equiva-
lent TCF activity to that detected in DKO mESCs (Figure 1E).
Stable expression of TCF4DN in DKO mESCs was remarkably
efficient in normalizing TCF reporter activity (Figure 1E), as was
stable expression of TCF1DN (Figure S1H).
To determine whether stable expression of TCF4DN efficiently
blocked the transcription of endogenous TCF-responsive genes,
we assessed transcript levels of Axin2, Brachyury, and Cdx1,
TCF target genes highly upregulated in DKO mESCs (Figure 1F;
Doble et al., 2007). The stable expression of TCF4DN in DKO
mESCs reduced the expression of TCF target genes to levels
that were equivalent to those observed in DKO-GSK-3bmESCs.
Suppression of Brachyury and Cdx1 expression was also
attained by overexpressing TCF1DN (Figure S1I).
Neither TCF4DN nor TCF1DN Rescue the DKO
Differentiation Blockade
We tested the differentiation capacity of DKO cell lines expressing
GSK-3b, TCF1DN, or TCF4DN by using embryoid body (EB) and
teratoma assays, as previously described (Doble et al., 2007).
We examined the expression of pluripotency markers Oct-4,
Sox-2, and Nanog, as well as the neurectoderm marker b-III-
tubulin, via immunofluorescent staining of whole EBs harvested
after 14daysof differentiation.DKOEBscontainednumerouscells
expressing Oct-4, Sox-2, and Nanog, and no cells expressing
b-III-tubulin, whereas EBs generated from DKO-GSK-3b mESCsell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc. 215
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Figure 1. Generation and Validation of Isogenic DKO mESC Lines Expressing GSK-3 Variants or Dominant-Negative TCF4
(A) Targeting steps used to create DKO mESCs, which incorporate an FRT recombination site for the Flp-in system in the GSK-3b locus.
(B) Flp-mediated site-specific integration of an EF-1a-driven transgene.
(C) Immunoblot analyses of transgene expression in mESC lines expressing TCF4DN or variants of GSK3.
(D) Morphology of WT, DKO, and DKO-Flp-in lines as indicated, via light microscopy. Scale bar represents 100 mm.
(E) TCF reporter assays demonstrate that re-expression of GSK3 in DKOmESCs restores steady-state inhibition of Wnt signaling (left) and that reporter activity is
not altered by the expression of kinase-inactive GSK3 (K85A) but is efficiently attenuated by expression of TCF4DN in DKO cells (right).
(F) Quantitative RT-PCR analysis of Axin2, Brachyury, and Cdx1 transcript levels in the indicated cell lines.
Bars represent the mean of three independent experiments ± SEM. See also Figure S1.
Cell Stem Cell
TCF-Independent b-Catenin Signaling in mESCscontained extensive regions of b-III-tubulin staining but lacked
cells expressing Oct-4, Sox-2, and Nanog (Figure 2A). DKO-
TCF4DN EBs displayed the same staining pattern as DKO EBs
for Oct-4, Sox-2, Nanog, and b-III-tubulin (Figure 2A). DKO-
TCF1DNEBsalsodisplayedextensive regionsofOct-4 andNanog
stainingand lackedb-III-tubulin andGFAPstaining.This resultwas
virtually indistinguishable from that obtained in a parallel experi-
ment done with DKO-TCF4DN EBs (Figure S2A).216 Cell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc.ControlWT teratomascontainedexamplesofall threegerm line-
ages in H&E-stained sections, as did teratomas generated from
DKO-GSK-3b mESCs (Figure 2B). By contrast, DKO-GSK-3b-
K85A or DKO-TCF4DN teratomas were composed of carci-
noma-like solid nodular structures with scant intervening stroma
(Figure 2B). There were no obvious histological differences
between DKO, DKO-GSK-3b-K85A, DKO-TCF4DN, or DKO-
TCF1DNteratomas (Figure2B;FigureS2B). Immunohistochemical
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Figure 2. Attenuation of Wnt Target Gene Activation in DKO mESCs, by Stably Expressing TCF4DN, Fails to Rescue Their Impaired
Differentiation
(A) Retention of the pluripotencymarkers Oct4, Nanog, and Sox2 aswell as expression of the neuronal marker b-III-tubulin was determined by immunofluorescent
staining of the indicated EBs, maintained under differentiating conditions for 14 days.
(B) H&E staining of 3-week teratomas derived from WT (E14K), DKO-GSK3b, DKO-GSK3b-K85A, and DKO-TCF4DN mESCs.
(C) Immunohistochemical staining of teratomas revealed retention of the pluripotency marker Nanog and absence of neural tissue, as determined by staining for
b-III-tubulin and GFAP, in teratomas derived from DKO-TCF4DN mESCs.
(D) b-catenin is maintained at low levels in teratomas derived from WT mESCs, whereas some regions of high b-catenin levels are observed in DKO-GSK3b
teratomas, resulting from the loss of GSK3b transgene expression and reversion to DKO phenotype. In contrast, b-catenin levels remain high in
DKO-GSK3b-K85A and DKO-TCF4DN teratomas.
Scale bars represent 20 mm (A) or 200 mm (B–D). See also Figure S2.
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TCF-Independent b-Catenin Signaling in mESCsstaining of teratoma sections for Nanog and b-III-tubulin sup-
ported our findings in EBs. Control (WT) teratomas lacked Nanog
but stained extensively forb-III-tubulin andGFAP (Figure 2C). TheCsame pattern of staining was observed in DKO-GSK-3b tera-
tomas (Figure 2C). DKO-GSK-3b-K85A teratomas lacked stain-
ing for b-III-tubulin or GFAP, but did stain extensively for Nanog.ell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc. 217
Cell Stem Cell
TCF-Independent b-Catenin Signaling in mESCsDKO-TCF4DN teratomas displayed the same pattern of Nanog,
b-III-tubulin, and GFAP staining as DKO-GSK-3b-K85A tera-
tomas, with perhaps evenmore retention of Nanog-positive cells
(Figure 2C). Teratomas derived fromDKO-TCF1DNmESCswere
virtually indistinguishable from those obtained fromDKOmESCs
(FigureS2C).OurOct-4 antibodywas incompatiblewith immuno-
histochemistry, but wewere able to detect Oct-4 inwestern blots
with lysates from DKO, DKO-GSK-3b-K85A, and DKO-TCF4DN
(but not WT or DKO-GSK-3b) teratomas (Figure S2D).
DKO-GSK-3b-K85A and DKO-TCF4DN teratomas had
extremely high levels of b-catenin in all cellular compartments,
in contrast to WT teratomas, which had much less intense stain-
ing (Figure 2D). DKO-GSK-3b teratomas contained large regions
with b-catenin staining resembling that of WT teratomas, but
they also contained regions where b-catenin levels were quite
high in all cellular compartments (Figure 2D), suggesting limited
loss of transgene expression during the 3 week period of tera-
toma generation.
DKO-TCF4DN mESCs Self-Renew in the Absence
of Serum and LIF
In addition to examining their differentiation potential through EB
and teratoma analyses, we characterized the self-renewal prop-
erties of DKO and DKO-TCF4DN mESCs and found that both
lines could be maintained indefinitely (nearly 1 year to date) in
basal N2B27 medium (Ying and Smith, 2003). Wild-type or
DKO-GSK-3b mESCs could not be passaged in N2B27 more
than twice before succumbing to differentiation and death,
whereas DKO and DKO-TCF4DN mESCs could initially be
passaged at split ratios of 1:5 (first two passages) and could
then be passaged at a reduced split ratio (1:2 or 1:3). With pro-
longed culture in N2B27, the growth rate of DKO and DKO-
TCF4DNmESCs decreased dramatically, as did their adherence
to gelatin-coated tissue culture dishes. Still, both cell lines were
propagated as loosely adherent spheres, amenable to disaggre-
gation with Accutase and replating as single-cell suspensions
every 2–3 weeks at a split ratio of 1:2 to 1:3. Incredibly, the
DKO-TCF4DN mESCs, maintained in N2B27 for more than
five passages, still retained expression of Oct-4, Sox2, and
Nanog as assessed by western blotting, whereas DKO mESCs
lost expression of Nanog and Sox2 (Figure S3A). Intriguingly,
the loss of Nanog and Sox2 expression in DKO mESCs could
be reversed by passaging the cells four times in standard
medium containing serum and LIF (‘‘DKO-R;’’ Figure S3A).
Immunofluorescent staining of DKO-TCF4DN mESCs main-
tained in N2B27 revealed that a subpopulation of cells was
doubly positive for Oct-4 and Nanog (Figure S3B). Some of
the spheres comprising DKO mESCs gave rise to strongly
adherent, tightly packed sheets of small cells, whereas DKO-
TCF4DN mESCs did not produce cells with this phenotype
(Figure S3C).
DKO and DKO-TCF4DN mESCs Do Not Differentiate
in a Defined Neural Differentiation Assay
We assessed the neural differentiation potential of DKO and
DKO-TCF4DN mESCs through an established assay (Ying and
Smith, 2003). Whereas WT and DKO-GSK3b mESCs yielded
cells with a neural morphology, DKO and DKO-TCF4DN mESCs
did not (Figure 3A). Western blot (Figure 3B) and qRT-PCR anal-218 Cell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc.yses (Figure 3C) at 9 and 14 days after the initiation of neural
differentiation revealed that WT and DKO-GSK3b mESCs lost
the expression of Oct-4 and Nanog at the protein level and
gained the expression of the neural marker b-III-tubulin. By
contrast, DKO and DKO-TCF4DN mESCs maintained expres-
sion of Oct-4 and Nanog and failed to express b-III-tubulin at
detectable levels (Figures 3B and 3C). Expression of the
GSK3b and TCF4DN transgenes were maintained throughout
the assay, even in the absence of drug selection (Figure 3B).
WT andDKO-GSK3b, but not DKO or DKO-TCF4DNmESCs, ex-
hibited a dramatic loss of Oct-4, Nanog, and Sox2 transcripts,
concomitant with markedly increased expression of the neural
markers b-III-tubulin, Map2, and Pax6 (Figure 3C).
Stable Knockdown of b-Catenin Expression
in DKO-TCF4DN mESCs Eliminates the Blockade
to Neurectodermal Differentiation
To determine whether high levels of b-catenin, acting indepen-
dently of TCF-mediated gene activation, might underlie the
DKO phenotype, we used stable expression of short-hairpin
siRNAs (shRNAs) to knock down b-catenin in DKO-TCF4DN
mESCs. Two different shRNA constructs were highly effective
at reducing cytosolic b-catenin in DKO-TCF4DN mESCs, to
levels just slightly higher than those detected in DKO-GSK-3b
mESCs (Figure 4A). Two negative control cell lines were ineffec-
tive in reducing cytosolic b-catenin levels (b-sh ctrl #1 and #2,
respectively) (Figure 4A). b-catenin transcript levels were
reduced to approximately 25% of the levels detected in DKO-
TCF4DNmESCs by both b-catenin-specific shRNAs (Figure 4B).
Microscopic observation revealed that the reduction in b-catenin
levels changed the gross morphology of the DKO-TCF4DN
mESC colonies. Colonies of DKO-TCF4DN-b-sh (ctrl #1 and
#2) mESCs remained highly refractile and individual cells were
tightly packed in the colonies, whereas colonies with reduced
b-catenin expression were less refractile and were comprised
of cells that tended to flatten out (Figure 4C). Immunofluorescent
staining for b-catenin confirmed that the total levels of b-catenin
were reduced in cells expressing the shRNAs targeting b-catenin
(Figure 4D). The nuclear b-catenin immunoreactivity observed
in DKO-TCF4DN-b-sh ctrl mESCs was dramatically reduced in
cells expressing the b-catenin-specific shRNAs, whereas the
junctional b-catenin levels remained high (Figure 4D). DKO-
TCF4DN-b-shmESCs retained strong nuclear staining for Nanog
(Figure 4D).
We used the teratoma assay to assess the differentiation
capacity of DKO-TCF4DN-b-sh mESCs. It was evident from
H&E-stained sections that knocking down b-catenin in DKO-
TCF4DN mESCs resulted in a dramatic change in the ability of
these cells to differentiate. Unlike DKO-TCF4DN-b-sh control
mESCs, which formed very homogeneous teratomas resembling
DKO teratomas, DKO-TCF4DN-b-sh teratomas displayed exam-
ples of differentiated tissues of all three germ layers (Figure 4E).
DKO-TCF4DN-b-sh control teratomas were indistinguishable
from DKO-TCF4DN teratomas when assayed for retention of
immunohistochemical staining for Nanog and lack of positive
staining for b-III-tubulin (compare Figures 2C and 4F). By
contrast, DKO-TCF4DN-b-sh teratomas did not contain
Nanog-positive cells but did have large regions of b-III-tubulin-
positive staining (Figure 4F). The effectiveness and persistence
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Figure 3. Attenuation of b-Catenin/TCF Target Gene Activation in DKOmESCs Does Not Restore Their Ability to Give Rise to Neurectoderm
in a Defined Neural Differentiation Assay
(A) Morphology of DKO, WT, DKO-GSK3b, and DKO-TCF4DN mESCs 9 days after the initiation of neural differentiation in N2B27 medium.
(B and C) The indicatedmESC lines were subjected to western blot (B) and qRT-PCR (C) analyses at 9 and 14 days after being seeded in N2B27medium.WT and
DKO-GSK3b mESCs exhibited robustly increased expression of the neuronal markers b-III-tubulin, Map2, and Pax6 and reduced expression of Oct-4, Nanog,
and Sox2, whereas DKO and DKO-TCF4DN mESCs retained Oct-4, Nanog, and Sox2 and failed to express b-III-tubulin, Map2, and Pax6. Bars represent
n = 3 ± SEM.
See also Figure S4.
Cell Stem Cell
TCF-Independent b-Catenin Signaling in mESCsof b-catenin knockdown was apparent by staining DKO-
TCF4DN-b-sh teratoma sections for b-catenin (Figure S5A).
We attempted to differentiate DKO-TCF4DN-b-sh mESCs into
neurons by using the defined N2B27 conditions described
above. Despite retention of b-catenin knockdown, the DKO-
TCF4DN-b-sh cells did not give rise to cells expressing neural
markers under these specific conditions (Figure S4), suggesting
that factors present in the microenvironment of teratomas are
required for neural differentiation to occur.CKnockdown of b-Catenin in DKO mESCs Does Not
Require Synergism with TCF4DN to Elicit Its Effects
on Differentiation
To determine whether the rescue of neurectoderm differentiation
obtained with b-catenin knockdown required the synergistic
suppression of TCF target gene expression, we took advantage
of the reversibility of the Flp-in system. We used transient Flp
expression to ‘‘Flp-out’’ the cassette encoding TCF4DN in
DKO-TCF4DN-b-sh cell lines. We confirmed the absence ofell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc. 219
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Figure 4. Knockdown of b-Catenin in DKO mESCS Expressing TCF4DN Partially Rescues Differentiation into the Neural Lineage
(A) Stable expression of b-catenin-specific short hairpin RNAs (shRNAs) reduces cytosolic b-catenin protein levels to approximately that of DKO-GSK3bmESCs.
Two negative controls were assayed, including empty vector (b-sh cont. #1) and b-catenin scrambled shRNA (b-sh cont. #2) alongside two distinct b-catenin-
specific shRNAs (b-sh #1 and b-sh #2).
(B) Validation of b-catenin knockdown by qRT-PCR. Bars represent n = 3 ± SEM.
(C) Morphology of DKO-TCF4DN b-sh ctrl #1 and DKO-TCF4DN b-sh #2mESCs grown on gelatin-coated culture dishes. Inset highlights the flatter morphology of
b-catenin knockdown DKO-TCF4DN mESCs. Scale bar represents 200 mm.
(D) Immunofluorescent staining of b-catenin knockdown DKO-TCF4DN mESCs reveals a significant reduction in the cytosolic and nuclear b-catenin pools as
a result of shRNA expression.
(E) H&E staining of DKO-TCF4DN-b-sh ctrl #1, DKO-TCF4DN-b-sh #1, and DKO-TCF4DN-b-sh #2 teratomas. Scale bar represents 200 mm.
(F) Immunohistochemical analyses of teratomas derived from b-catenin knockdown DKO-TCF4DN mESCs reveals that suppression of b-catenin alleviates the
differentiation blockade to the neural lineage. Scale bar represents 100 mm.
See also Figure S5.
Cell Stem Cell
TCF-Independent b-Catenin Signaling in mESCs
220 Cell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc.
Cell Stem Cell
TCF-Independent b-Catenin Signaling in mESCsTCF4DN and the retention of b-catenin shRNAs in Flp-out clones
through western blotting (Figure S5B). The extent of b-catenin
knockdown in Flp-out clones expressing either of the two b-cat-
enin shRNAswas unchanged from that which we observed in the
parental cell lines (Figure S5B).
We used the teratoma assay to determine whether reduction
of b-catenin levels in DKO mESCs would be sufficient to rescue
blocked neuronal differentiation. DKO-TCF4DN Flp-out tera-
tomas expressing a negative control shRNA displayed high
levels of Nanog immunostaining and no staining for b-III-tubulin
(Figure S5C). By contrast, DKO-TCF4DN Flp-out teratomas with
normalized b-catenin levels did not retain Nanog and differenti-
ated readily to neurectoderm as assessed by b-III-tubulin stain-
ing (Figure S5C). Thus, suppression of b-catenin levels alonewas
sufficient to rescue neurectodermal differentiation of DKO
mESCs in this assay.
Overexpression of Stabilized b-Catenin in WT mESCs
Inhibits Neuronal Differentiation and Delays Loss of
Pluripotency
To determine whether overexpression of stabilized b-catenin in
wild-type mESCs would phenocopy DKOmESCs, we generated
stable cell lines overexpressing stabilized (S33A) b-catenin (Liu
et al., 2002; Takao et al., 2007). We obtained several indepen-
dent cell lines in which stabilized b-catenin levels were equiva-
lent to those detected in DKO mESCs (Figure S6A). Selected
cell lines expressing high levels of b-cateninS33A yielded TCF
reporter activities (Figure S6B) and transcript levels of the TCF
target genes Axin2, Brachyury, and Cdx1 (Figure S6C), which
were even higher than in DKO mESCs (Figure S6B).
b-cateninS33A-expressing mESCs were morphologically
indistinguishable from DKO mESCs (Figure 5A). They also dis-
played impaired neuronal differentiation, based on immunuo-
fluorescent staining for b-III-tubulin (Figure 5B) and qRT-PCR
analyses (Figure 5C) of neuronal markers in EBs after 14 days
of differentiation. Teratomas generated from b-cateninS33A
mESCs also displayed a dramatic reduction in detectable
neuronal tissue (Figure 5D).
We also carried out short-term differentiation experiments to
dissect early loss of pluripotency events. We found that protein
levels of Nanog and Sox2 were almost undetectable in WT
control cells after 72 hr in EB/differentiation medium or N2B27
basal medium (Figure 5E). By contrast, DKO and WT-b-cate-
ninS33A mESCs strongly retained protein expression of Nanog,
Sox2, and Oct-4 after the same treatment (Figure 5E).
A b-Catenin Mutant Lacking Its TCF-Transactivating
Domain Inhibits Neural Differentiation and Sustains
Pluripotency
We stably overexpressed a C-terminal truncation mutant of
b-catenin (b-cateninS33ADC) that lacks the domain necessary
for transactivation of b-catenin/TCF target genes (Figures 6A
and 6B; Kolligs et al., 1999; Takao et al., 2007). b-catenin-
S33ADC overexpression activated a TCF reporter 10-fold less
efficiently than b-cateninS33A (Figure 6C) and only weakly
induced the expression of the b-catenin/TCF target genes
Axin2, Brachyury, and Cdx1 (Figure 6D). Strikingly, b-catenin-
S33ADC mESCs appeared morphologically indistinguishable
from those expressing b-cateninS33A (Figure 6E).CTo address whether b-cateninS33ADC mESCs exhibited sus-
tained pluripotency and blocked differentiation, we carried out
short-term differentiation experiments (Figure 6F), as was done
previously for mESCs expressing b-cateninS33A (Figure 5E).
After 72 hr of culture in either EB or N2B27 medium, b-catenin-
S33ADC mESCs retained the expression of Oct-4, Sox2, and
Nanog, whereas WT control mESCs displayed highly reduced
levels of Sox2 and Nanog. Moreover, EBs generated from b-cat-
eninS33ADC mESCs had sustained expression of Oct-4 and
Nanog and lacked b-III-tubulin expression, after 10 days of
differentiation, as determined by immunofluorescent staining
(Figure 6G) and qRT-PCR analyses (Figure 6H). Collectively,
these data further support that transactivation of b-catenin/
TCF target genes is not requisite for b-catenin to block differen-
tiation and maintain the pluripotent state of mESCs.
Stabilization of b-Catenin Induces the Formation
of b-Catenin/Oct-4 Complexes
It has been previously suggested that Oct-4 and b-catenin can
interact (Takao et al., 2007) and we sought to determine whether
such an interaction could underlie, in part, the profound inability
of DKO mESCs to differentiate efficiently. We used coimmuno-
precipitation experiments to probe b-catenin/Oct-4 interactions
under a variety of conditions. Oct-4 immunoprecipitates pre-
pared from lysates of WT mESCs did not contain readily detect-
able levels of b-catenin, as determined by western blotting
(Figure 7A). Strikingly, by using lysates from DKO mESCs, or
wild-type mESCs treated for 48 hr with the GSK-3 inhibitor
CHIR99021, b-catenin was easily detectable in Oct-4 immuno-
precipitates (Figure 7A). Reciprocal coimmunoprecipitations
with a b-catenin antibody contained a small amount of detect-
able Oct-4, which did not change appreciably in lysates obtained
from WT, DKO, or CHIR99021-treated WT mESCs (Figure 7A).
One possible explanation for this result is that the antibody
used for b-catenin immunoprecipitation binds an epitope on
b-catenin that precludes its efficient coimmunoprecipitation
with Oct-4. CHIR99021 treatment dramatically altered the
morphology of WT mESC colonies on gelatin-coated plates,
such that they resembled colonies formed by DKO mESCs
(Figure 7A).
We examined whether activation of the Wnt/b-catenin
signaling pathway with Wnt3a could enhance the formation of
Oct-4/b-catenin complexes. A low level of b-catenin/Oct-4
coimmunoprecipitation was detected with WT mESC lysates
(Figure 7B). However, b-catenin and Oct-4 formed an easily
detectable complex after overnight treatment of WT mESCs
with Wnt3a-conditioned medium (CM) (Figure 7B). Stable
expression of TCF4DN in DKO mESCs did not attenuate the
interaction between Oct-4 and b-catenin, whereas reducing
b-catenin levels in DKO-TCF4DN mESCs through shRNA-medi-
ated knockdown reduced the amount of b-catenin complexed
with Oct-4 (Figure 7C). Overexpression of stabilized b-catenin
(S33A) in wild-type mESCs also resulted in increased coimmu-
noprecipitation between Oct-4 and b-catenin (Figure 7D). Our
ability to detect Oct-4 in b-catenin immunoprecipitates was
highly dependent on which b-catenin antibody was used, as is
evident from Figure 7A using a mouse monoclonal antibody,
versus Figures 7B–7D using a rabbit polyclonal antibody. Oct-
4 protein levels in whole-cell lysates from WT and GSK-3-nullell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc. 221
WT-Control
-
III
-T
u
bu
lin
D
ap
i
WT- -catS33A cl. A3 WT- -catS33A cl. B2A BWT-Control
WT- -catS33A cl. A3 WT- -catS33A cl. B2
DKO
C
3 2
0
5
10
15
R
el
at
iv
e 
Tr
an
sc
rip
t L
ev
el
s
o 3 2
0
20
40
60
80
R
el
at
iv
e 
Tr
an
sc
rip
t L
ev
el
s
o 3 2
0
10
20
30
R
el
at
iv
e 
Tr
an
sc
rip
t L
ev
el
s
3 2
0
2
4
6
8
R
el
at
iv
e 
Tr
an
sc
rip
t L
ev
el
s
3 2
0
2
4
6
8
R
el
at
iv
e 
Tr
an
sc
rip
t L
ev
el
s
o 3 2
0
2
4
6
R
el
at
iv
e 
Tr
an
sc
rip
t L
ev
el
s
-III-Tubulin Map2 Nurr1Nestin
Tyrosine 
Hydroxylase
D
W
T-C
on
tro
l
W
T-
ca
tS3
3A
 
cl.
 A3
W
T-
ca
tS3
3A
 
cl.
 B
2
+LIF
15% FBS
72 hrs
-LIF
5% FBS
72 hrs
WB: Nanog
WB: Oct-4
WB: -Tubulin-I
WB: Sox2
N2B27
72 hrs
E
WT-Control WT- -cat S33A cl. A3 WT- -cat S33A cl. B2 WT
-
Co
ntr
ol
W
T-
ca
tS3
3A
 
cl.
 
A3
DK
O
W
T-
ca
tS3
3A
 
cl.
 B
2
W
T-C
on
tro
l
W
T-
ca
tS3
3A
 
cl.
 A3
DK
O
W
T-
ca
tS3
3A
 
cl.
 B
2
W
T-C
on
tro
l
W
T-
ca
tS3
3A
 
cl.
 A3
DK
O
W
T-
ca
tS3
3A
 
cl.
 B
2
W
T-C
on
tro
l
W
T-
ca
tS3
3A
 
cl.
 A3
W
T-
ca
tS3
3A
 
cl.
 B
2
W
T-C
on
tro
l
W
T-
ca
tS3
3A
 
cl.
 
A3
W
T-
ca
tS3
3A
 
cl.
 B
W
T-C
on
tro
l
W
T-
ca
tS3
3A
 
cl.
 
A3
W
T-
ca
tS3
3A
 
cl.
 B
2
W
T-C
on
tro
l
W
T-
ca
tS3
3A
 
cl.
 
A3
W
T-
ca
tS3
3A
 
cl.
 B
2
W
T-C
on
tro
l
W
T-
ca
tS3
3A
 
cl.
 
A3
W
T-
ca
tS3
3A
 
cl.
 B
2
Figure 5. Expression of Stabilized b-Catenin in WT mESCs Inhibits Neural Differentiation and Prolongs the Retention of Pluripotency
(A) Morphology of WTmESCs expressing stabilized b-catenin (WT-b-catS33A, independent clones A3 and B2), relative to control mESCs stably transfected with
empty vector (WT-Control) and DKO mESCs. Scale bar represents 100 mm.
(B) Immunofluorescent staining of day 14 EBs reveals that b-catenin-overexpressing EBs fail to generate neural tissue, as determined by staining for the neural
marker b-III-tubulin. Scale bar represents 20 mm.
(C) qRT-PCR analyses of several neural markers in day 14 EBs derived from control and b-catenin-overexpression mESCs demonstrates that b-catenin
overexpression inhibits the expression of neural-specific genes. Bars represent n = 3 ± SEM.
(D) Teratomas derived from b-catenin-overexpressing mESCs failed to generate neural tissue in vivo, as determined by immunohistochemical staining for
b-III-tubulin. Scale bar represents 500 mm.
(E) b-catenin overexpression prolongs the retention of the pluripotency markers (Oct-4, Nanog, and Sox2) under conditions promoting differentiation (72 hr
incubation).
See also Figure S6.
Cell Stem Cell
TCF-Independent b-Catenin Signaling in mESCsmESCs are equivalent (Figure S1F). Thus, the increased Oct-
4/b-catenin coimmunoprecipitation detected in mESCs with
activated Wnt/b-catenin signaling, well exemplified by DKO
mESCs, was not due to increased levels of Oct-4 protein.
b-Catenin Enhances Oct Activity
To determine whether b-catenin stabilization through various
means could affect Oct activity, we utilized a dual-luciferase-222 Cell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc.based Oct reporter assay based on six tandem repeats of the
palindromic Oct factor recognition element (PORE) (Tomilin
et al., 2000). The Oct reporter was efficiently activated by
CHIR99021 (15-fold), Wnt3a-CM (6-fold), overexpression of
b-cateninS33A (8-fold), or genetic ablation of GSK-3a/b
(8-fold) (Figure 7E). We also observed an increase in transcript
levels for the direct Oct-4 target genes Nanog, Tbx3, Tcfcp2L1,
and PDGFa (Chen et al., 2008; Mathur et al., 2008; Sharov et al.,
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Figure 6. A b-Catenin Truncation Mutant Lacking Its TCF Transactivation Domain Sustains Pluripotency
(A) Schematic of full-length b-catenin (b-catS33A; aa 1–781) and the C-terminal deletion mutant (b-catS33ADC; aa 1–694) used in this study.
(B) Relative protein levels of myc-tagged b-catS33A and b-catS33ADC transgenes in mESC lines.
(C and D) TCF reporter assays (C) and qRT-PCR analysis of the b-catenin/TCF targets Axin2, Brachyury, and Cdx1 (D) demonstrate that b-catS33ADC activates
b-catenin/TCF signaling 10-fold less than full-length b-catS33A in mESC lines.
(E) Morphology of WT-Control, b-catS33A, and b-catS33ADC mESCs grown on gelatin-coated dishes.
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Cell Stem Cell
TCF-Independent b-Catenin Signaling in mESCs2008) upon treatment of wild-type mESCs with CHIR99021,
although the expression of another target gene, Gdf3, was
unchanged (Figure 7F). Importantly, b-cateninS33ADC retained
the ability to interact with Oct-4 (Figure 7G) and activated an
Oct reporter (PORE) with efficiency similar to that of full-length
b-catenin (Figure 7H).
DISCUSSION
Taken together, our findings suggest that b-catenin, acting inde-
pendently of TCF/LEF factors, can reinforce the pluripotent
status of mESCs and impair their efficient differentiation. The
role of Wnt/b-catenin signaling in ESC pluripotency has been
somewhat controversial. Long-term Wnt/b-catenin signaling
promotes mesendodermal differentiation of ESCs (Bakre et al.,
2007; Lindsley et al., 2006), whereas short-term treatment of
ESCs with the GSK-3 inhibitor BIO or Wnt-3a enhances pluripo-
tency of mouse and human ESCs (Sato et al., 2004). Expression
of Wnt ligands and receptors has been detected through in situ
hybridization in the inner cell mass of mouse blastocysts, and
active b-catenin has been detected in the nuclei of mouse blas-
tocysts via immunofluorescence visualization (Kemp et al., 2005;
Xie et al., 2008), suggesting that Wnt/b-catenin signaling plays
a physiological role in the tissues from which ESCs are derived.
It has been reported that Wnt/b-catenin signaling can syner-
gize with LIF/Stat3 signaling to sustain pluripotency in mESCs
(Ogawa et al., 2006). The role of LIF/Stat3 signaling in embryonic
stem cell maintenance has been linked to the blockade of mes-
endodermal differentiation (Ying et al., 2003). Our model, in
which b-catenin directs mesendodermal differentiation through
TCF-mediated signaling and promotes pluripotency through
a TCF-independent mechanism, can help to explain the
observed synergism between LIF and Wnt/b-catenin signaling.
Recently, it has been discovered that GSK-3 inhibitors
(CHIR99021 or BIO) greatly enhance the ability to establish de
novo mESC cell lines from C57BL/6 blastocysts (Gertsenstein
et al., 2010; Kiyonari et al., 2010; Sato et al., 2009). Previously, it
had been very difficult to obtain germline-competent mESC lines
from C57BL/6 mice via standard mESC culture conditions. De
novoembryonic stemcell isolation fromrats,whichhasbeennoto-
riously difficult, has also been facilitated with GSK-3 inhibitor
supplementation (Buehr et al., 2008; Li et al., 2009). Taken
together, and given the strong link between GSK-3 inhibition and
b-catenin accumulation/activation, these studies strongly support
a role for stabilized b-catenin in the positive regulation of pluripo-
tency inmESCs. It is also important to note that the ‘‘ground state’’
of mESC pluripotency requires defined medium, which must be
supplemented with an inhibitor of GSK-3 (Ying et al., 2008).
Whereas it is widely assumed that most of the signaling func-
tions of b-catenin rely on its interaction with TCFs, b-catenin can
bind several other nuclear proteins to elicit biological effects
(Le et al., 2008). These alternative b-catenin signaling modes(F) Expression of b-catS33ADC in WT mESCs sustains the retention of pluripote
(G) Immunofluorescent staining reveals that stable expression of b-catS33ADC
promotes the retention of Oct-4 and Nanog in day 10 EBs.
(H) qRT-PCR analyses of several neural markers in day 10 EBs derived from the
b-catS33ADC overexpression inhibits the expression of neural-specific genes.
(C, D, and H) Bars represent n = 3 ± SEM.
224 Cell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc.could explain some of our observations. We provide evidence
suggesting that b-catenin’s interaction with the pluripotency
regulator Oct-4 at least partially underlies its effects on
sustaining pluripotency. Our qRT-PCR data reveal that not all
Oct-4 target genes are upregulated under conditions that elevate
active b-catenin levels. Thus, only a subset of Oct-4 target
genes, including the key pluripotency regulator Nanog, is prob-
ably coregulated by b-catenin. The precise mechanism through
which b-catenin selectively activates specific Oct-4 targets
remains to be identified.
Of note, two recent studies endeavoring to elucidate the Oct-4
protein interaction network inmESCs failed to isolateb-catenin as
a high-confidence Oct-4 interactor (Pardo et al., 2010; van den
Berg et al., 2010). This is probably because both studies were
performed in the absence ofWnt pathway stimulation, conditions
under which the majority of cellular b-catenin would be
membrane associated and spatially isolated from nuclear Oct-4.
We cannot discount the possibility that b-catenin knockdown
may have influenced E-cadherin-mediated cell adhesion in our
system (Nelson, 2008). Reduced E-cadherin-mediated intercel-
lular adhesion has recently been reported to reduceNanog levels
and to promote mESC differentiation (Chou et al., 2008). Consis-
tent with this, E-cadherin cell-cell contacts are required for the
induction of pluripotency in iPSCs (Chen et al., 2010). Thus,
b-catenin’s junctional role in DKO mESCs could partly regulate
the ability of the cells to exit the pluripotent state, independent
of its nuclear functions.
Through western blot analyses, we were able to detect all four
members of the TCF/LEF family in mESCs expressing GSK-3 or
lacking it entirely. Based on our TCF reporter assays and TCF
target gene analyses, our dominant-negative strategies
with TCF1DN and TCF4DN appear to have efficiently blocked
b-catenin/TCF/LEF activity contributed by all family members,
which is not unexpected given that the DNA binding domains
of the TCF family members are nearly identical (Arce et al.,
2006). The best-studied TCF/LEF family member in mESCs is
TCF3, which acts as a transcriptional repressor of Nanog and
possibly other genes involved in mESC self-renewal (Pereira
et al., 2006; Tam et al., 2008; Yi et al., 2008). TCF3 is atypical
in that its repressive function appears to be retained in the pres-
ence of stabilized b-catenin (Pereira et al., 2006). Thus, the highly
elevated TCF activity detected in DKO cells is probablymediated
by other TCF/LEF family members, suggesting that they are the
primary effectors of Wnt/b-catenin signaling in mESCs. Stable
expression of dominant-negative LEF1 (analogous to TCF1DN
and TCF4DN used in our study) in wild-type mESCs does not
appear to have a profound effect on the ability of the mESCs
to self-renew in standard serum-containing or fully defined
serum-free medium (Ying et al., 2008). Thus, although mESCs
harbor all TCF family members, they probably do not play an
active role in sustaining pluripotency but may be poised to relay
Wnt signals promoting differentiation.ncy markers under conditions promoting differentiation (72 hr incubation).
in WT mESCs inhibits the expression of the neural marker b-III-tubulin and
indicated control and b-catS33A overexpression mESCs demonstrates that
Figure 7. Stabilized Full-Length or C-Terminal Truncated b-Catenin Forms a Complex with Oct-4 that Is Coincident with Increased Oct-4
Activity
(A) Morphology of WT mESCs after treatment with CHIR99021 (15 mM for 48 hr; left). Western blots for b-catenin and Oct-4 after control, Oct-4, and b-catenin
immunoprecipitates from the indicated cell lines (right).
(B) b-catenin coimmunoprecipitates with Oct-4 from WT mESC lysates after overnight stimulation with Wnt3a-CM.
(C) b-catenin coimmunoprecipitates with Oct-4 from DKO and DKO-TCF4DN mESC lysates, but negligibly from lysates of DKO-TCF4DN mESCs expressing
b-catenin-specific shRNAs.
(D) b-catenin coimmunoprecipitates with Oct-4 from lysates derived from WT mESCs expressing stabilized (S33A) b-catenin.
(E) Wnt/b-catenin pathway activation by various means induces the activation of an Oct-4 reporter (PORE).
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Cell Stem Cell
TCF-Independent b-Catenin Signaling in mESCsOur experiments revealed that DKO cells are capable of prolif-
erating indefinitely in serum-free medium, although they lose
protein expression of Nanog and Sox2, suggesting that they
are no longer pluripotent. Intriguingly, the DKO cells can be re-
turned to a pluripotent state by switching back to medium with
serum and LIF, suggesting that extrinsic factors are sufficient
to ‘‘reprogram’’ them. The loss of Nanog and Sox2 proteins
from DKO cells maintained in N2B27 medium was prevented,
at least in a subset of cells, by blocking TCF activity through
expression of TCF4DN. This suggests that TCF-mediated gene
activation plays a prodifferentiation role. Indeed, sustained
Wnt-b-catenin signaling has been shown to direct mESCs into
mesendodermal progenitors, in part through TCF-mediated acti-
vation of brachyury and sox17 transcription (Bakre et al., 2007).
Based on our collective data, we propose a model whereby
b-catenin signaling plays a supportive role, in part through its
interaction with Oct-4, in the maintenance of ground state pluri-
potency (Figure 7I). This role of b-catenin does not involve its
transactivation of TCF/LEF-mediated transcription, which
serves to promote mesendodermal differentiation. Given that
b-catenin has been linked to the self-renewal of somatic stem
cells and cancer-initiating cells (reviewed in Fodde and Brabletz,
2007), our findings have important implications not only for
embryonic stem cell biology but also for cancers arising from
dysregulation of Wnt/b-catenin signaling.
EXPERIMENTAL PROCEDURES
Generation of a GSK-3a/b Double-Knockout Flp-in Cell Line
The GSK-3b locus, in a previously generated GSK-3a/ mESC line, was
sequentially targeted to create a DKO line compatible with the Flp-in system
(Invitrogen).
Immunofluorescence Analysis
Staining of cells grown on coverslips was performed as previously described
(Doble et al., 2007). See Supplemental Experimental Procedures for staining
of embryoid bodies.
Coimmunoprecipitation Assays
Coimmunoprecipitation experiments were performed essentially according to
the manufacturer’s instructions for Dynabeads Protein G (Invitrogen).
Neural Differentiation Assays
The neural differentiation experiment was performed as described previously
(Ying and Smith, 2003).
Self-Renewal Assay
Cells in standard, serum-containing medium were disassociated with Accu-
tase (Innovative Cell Technologies), washed with PBS, and resuspended in(F) WT mESCs treated with CHIR99021 for 24 hr displayed a significant increas
qRT-PCR (p < 0.05, unpaired t test).
(G) Coimmunoprecipitation analysis demonstrates that b-catS33ADC retains the
(H) Increased activation of an Oct reporter (PORE) in WT mESCs stably expressi
(I) Model of b-catenin action in mESCs. (i) In the absence of Wnt pathway activatio
of nuclear b-catenin associates with some Oct-4-regulated loci. Under condition
tiation. (ii) Under conditions where the signaling pool of b-catenin is stabilized, nuc
TCF or Oct-4. In this scenario, mESCs exhibit enhanced self-renewal, in part beca
entiation, resulting from high levels of TCF target gene expression caused by b-c
activation, via ectopic expression of a dominant-negative TCF protein (TCFDN), i
enhances retention of pluripotency markers. (iv) mESCs expressing a truncation m
for the efficient transactivation of b-catenin/TCF target genes, exhibit enhanced s
refractory to neurectoderm differentiation.
226 Cell Stem Cell 8, 214–227, February 4, 2011 ª2011 Elsevier Inc.serum-free N2B27 medium (see Neural Differentiation Assay section). Serum
was not used subsequently in any of the cell maintenance procedures. Cells
were plated on gelatin-coated dishes and maintained at 37C in a humidified
incubator with 5% CO2. Cells were passaged when subconfluent with Accu-
tase. The medium was changed every 2–3 days.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at
doi:10.1016/j.stem.2010.12.010.
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